These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28764902)

  • 21. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease.
    Lázaro DF; Pavlou MAS; Outeiro TF
    Exp Neurol; 2017 Dec; 298(Pt B):162-171. PubMed ID: 28526239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
    Kanaan NM; Manfredsson FP
    J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling Lewy pathology propagation in Parkinson's disease.
    Luk KC; Lee VM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S85-7. PubMed ID: 24262196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomic approach to studying Parkinson's disease.
    Zhang J; Goodlett DR
    Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.
    Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease.
    Bhattacharjee P; Öhrfelt A; Lashley T; Blennow K; Brinkmalm A; Zetterberg H
    J Proteome Res; 2019 May; 18(5):2109-2120. PubMed ID: 30943367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death.
    Lee JT; Wheeler TC; Li L; Chin LS
    Hum Mol Genet; 2008 Mar; 17(6):906-17. PubMed ID: 18065497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synphilin-1 is present in Lewy bodies in Parkinson's disease.
    Wakabayashi K; Engelender S; Yoshimoto M; Tsuji S; Ross CA; Takahashi H
    Ann Neurol; 2000 Apr; 47(4):521-3. PubMed ID: 10762166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental modelling of -synuclein aggregation and spreading in synucleinopathies.
    Bourdenx M; Dehay B; Bezard' E
    Bull Acad Natl Med; 2015 Jun; 199(6):797-808. PubMed ID: 29901880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease.
    Kardani J; Sethi R; Roy I
    Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1454-1463. PubMed ID: 28167231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.
    Jellinger KA
    Mov Disord; 2012 Jan; 27(1):8-30. PubMed ID: 22081500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
    Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
    Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.